Homocysteine is a sulfur-containing amino acid, which is synthesized from the precursor methionine through a multi-step process, and then reconverted to methionine or catabolyzed into cysteine. The presence of vitamin B9 (folic acid), vitamin B6 (pyridoxine) and vitamin B12 (cobalamin) is essential in homocysteine metabolism, wherein defi ciency of one or more of these nutrients is associated with various degree of hyperhomocysteinemia. There is little doubt that hyperhomocysteinemia is associated with several human disorders, such as cardiovascular disease, neurodegenerative disorders, pregnancy complications and fractures, so that its measurement might be useful for risk assessment. Nevertheless, several randomized homocysteine-lowering therapy trials have failed to show that supplementation with vitamins B substantially modifi es (and -more importantly -improves) the end points and the related outcomes. According to the current state of scientifi c knowledge, it seems thus reasonable to conclude that lowering homocysteine alone is probably insuffi cient to mitigate the risk of thromboembolic, cardiovascular and neurodegenerative disorders inasmuch as this bizarre amino acid acts in strict synergy with other probably more powerful risk factors. Several lines of evidence suggest, however, that its measurement may be helpful for identifying subjects at greater risk of disease, who may thus benefi t from a more aggressive treatment of other modifi able risk factors, as recently shown by result of the 5-year Fenofi brate Intervention and Event Lowering in Diabetes (FIELD) trial.
Homocysteine in health and disease
Homocysteine (Hcy) is a relatively simple sulfur-containing amino acid (HSCH 2 CH 2 CH[NH 2 ]CO 2 H), homologue to cysteine, from which it only differs for the presence of an adjunctive methylene group. Hcy cannot be considered as a traditional nutrient, since it needs to be endogenously synthesized from the precursor methionine through a multistep process which principally encompasses removal of the terminal C ε methyl group ( Figure 1 ) . The compound can then be alternatively reconverted to methionine, or converted into cysteine through processes catalyzed by methionine syntase or betaine homocysteine methyltransferase in the former case, and by cystathionine β -synthase in the latter, respectively. Throughout the metabolic cycle of Hcy, the presence of vitamins, such as vitamin B9 (commonly known as folic acid or folate), vitamin B6 (also known as pyridoxine) and vitamin B12 (also known as cobalamin) is essential ( Figure 1 ) (1) , so that defi ciency of one or more of these vitamins is associated with various degree of hyperhomocysteinemia. Other important determinants of serum Hcy concentration are genetic polymorphisms, especially those involving the enzyme methylenetetrahydrofolate reductase (MTHFR), methionine synthase, methionine synthase reductase, and cystathionine β -synthase (2) , as well as ageing, renal disease and cigarette smoking (3) .
The important contribution of homocysteine in human disease has been acknowledged since the early 1960s, when cases of homocystinuria were associated with vascular disorders. In particular, the analysis of archival cases of homocystinuria in 1933 and cobalamin C disease in 1968 led Kilmer S. McCully to fi rst hypothesize that Hcy may be involved in the pathogenesis of vascular disease by a direct effect of the amino acid on arterial cells and tissues (1) . This earlier conjecture has catalyzed a large number of cross-sectional and prospective studies over the ensuing decades, aimed to defi nitely establish whether this sulfur-containing amino acid could be considered a powerful predictor of cardiovascular disease. Before analyzing the potential association between Hcy and thrombosis, we should however bear in bind that the generic term " thrombosis " underlines rather different entities, i.e., venous (4) , arterial (5) and even lymphatic thrombosis (6) , which are characterized by a specifi c pathogenesis and only marginally share predisposing conditions and relative risk factors (7) . Although a certain condition may henceforth be considered a risk factor for arterial thrombosis (e.g., periodontal disease) (8) , it does not automatically translate into a risk factor for venous thrombosis and vice versa (e.g., antithrombin deficiency) (9, 10) . One notable exception is probably Hcy, since several studies have now contributed to raise the issue that hyperhomocysteinemia may be associated with both venous and arterial thrombosis. It is noteworthy that Hcy has also been implicated in the pathogenesis of other non-classically " thrombotic " disorders, including neurodegenerative diseases, such as Alzheimer ' s disease, vascular dementia, cognitive impairment or stroke (11, 12) , pregnancy complications (13) as well as bone loss, decreased bone strength, and increased risk of fracture (14) among others.
Where do we stand, now ?
The evidence of a link between hyperhomocysteinemia and different human disorders produced an unprecedented scale of clinical studies that were aimed to explore the epidemiological association of serum Hcy and venous thrombosis, cardiovascular disease, neurodegenerative disorders and pregnancy complications.
Venous thrombosis and cardiovascular disease
The most recent meta-analysis linking hyperhomocysteinemia with venous thrombosis was published by Den Heijer et al., who identifi ed case-control or nested case-control studies by searches of electronic literature for relevant reports published before July 2003 (15) . The following meta-analysis of 24 retrospective (n = 3289 cases) and three prospective studies (n = 476 cases) showed that a 5 μ mol/L higher measured Hcy level was associated with a 27 % [95 % confi dence interval (95 % CI) 1 % -59 % ] higher risk of venous thrombosis in prospective studies, and a 60 % (95 % CI 10 % -134 % ) higher risk in retrospective studies. The relationship between hyperhomocysteinemia and coronary heart disease has been eventually meta-analyzed by Humphrey, who performed a MEDLINE search 1966 through March 2006 for prospective cohort studies that measured Hcy and incidence of disease in the general adult population (16) . Twenty-six articles of good or fair quality were included in the fi nal model, which showed 20 % -50 % increased risk of coronary heart disease for each 5 μ mol/L higher measured Hcy level. The resulted combined risk ratio (RR) for coronary events was 1. Where do we go from here ?
Although the outcomes of most several meta-analyses seem to concur in attributing a clear role to Hcy in human disease, especially in cardiovascular or neurodegenerative disorders and pregnancy complications (Table 1 ), yet vast challenges remain to bridge the gap between epidemiological observation and interventional studies. Basically, it must be established as to whether Hcy can be effectively considered a " cause " of human pathology, an indirect " marker " , or both. The answer to this question is nothing but ancillary, since the lack of a causal relationship between hyperhomocysteinemia and disease would still fulfi l the basic requirements for a justifying a population screening, but not for establishment of a widespread and even aggressive lowering therapy.
To establish whether Hcy-lowering intervention in patients with and without pre-existing cardiovascular disease is effective for preventing cardiovascular events and death, is safe for preventing cardiovascular events and differ in effi cacy or safety, Mart í -Carvajal performed a comprehensive search of randomized controlled trials with a follow-up period of 1 year or longer, including adults at risk of or with established cardiovascular disease, who were administered vitamin B6, B9 or B12 (alone or in combination) (26) . Eight randomized clinical trials, including 24,210 participants with a low risk of bias, were fi nally analyzed, yielding a RR of 1.03 (95 % CI 0.94 -1.13) for non-fatal or fatal myocardial infarction, 0.89 (95 % CI 0.73 -1.08) for stroke, and 1.00 (95 % CI 0.92 -1.09) for death by any cause, thus concluding that there is no suffi cient evidence to support the use of Hcy-lowering therapy for preventing cardiovascular events. Clarke et al. recently performed a meta-analysis of published results of eight Hcy-lowering trials for preventing vascular disease, including 37,485 patients and providing comparisons of the effects of B vitamins on 5074 coronary heart disease events, 1483 stroke events, 2692 incident cancer events, and 5128 overall deaths (27) . Interestingly, allocation to B vitamins had no benefi cial effects on any cardiovascular events, with hazard ratios (HR) of 1.01 (95 % CI 0.96 -1.07) for coronary heart disease, 0.96 (95 % CI 0.87 -1.07) for stroke, 1.08 (95 % CI 0.99 -1.17) for cancer, and 1.02 (95 % CI 0.97 -1.07) for death from any cause. Hence it seems reasonable to conclude that although identifi cation of hyperhomocysteinemia might be somehow useful, lowering its concentration may not substantially modify (and -more importantly -improve) cardiovascular outcomes.
The effect of Hcy lowering by supplementation of B vitamins on the risk reduction of venous thromboembolism has been investigated by den Heijer in a randomized, placebocontrolled, double-blind trial (28) . Overall, the rate of recurrent venous thrombosis did not signifi cantly differ between patients treated with vitamins and those with placebo (i.e., 12.2 % vs. 14.3 % ). The relative HR associated with vitamin treatment was 0.84 (95 % CI 0.56 -1.26), thus showing that Hcy lowering therapy seems also ineffective to prevent venous thrombosis. Analogous results were obtained by Mei et al, who recently published the results of a metaanalysis of randomized controlled trials on the effect of Hcy lowering therapy and risk of cardiocerebrovascular events (29) . After comprehensive search of MEDLINE and OVID databases from January 1966 to December 2008, 17 trials involving 39,107 patients with cardio-and cerebrovascular disease were included, but results of the following metaanalysis failed to show any signifi cant difference between the intervention group and the control population, the RR for patients treated with folic acid or B vitamins supplementation compared with controls being 1.01 (95 % CI 0.97 -1.05) for overall cardiovascular events, 1.01 (95 % CI 0.94 -1.07) for coronary heart disease, and 0.94 (95 % CI 0.85 -1.04) for stroke. As regards neurodegenerative disorders, Hcy is indeed a surrogate marker for B vitamin defi ciency and a neurotoxic agent, so that the notion of improving clinical outcomes by lowering Hcy with B supplementation would be unquestionably appealing (11) . Likewise thrombotic disorders, the outcomes of two recent randomized placebo controlled trials are however disappointing. Sun et al. performed a randomized, double-blind, placebo-controlled study in Taiwanese patients with mild to moderate Alzheimer ' s dementia, and found that although a 26-week multivitamin supplement containing vitamins B6, B12 and folic acid was effective to decrease Hcy concentrations, no signifi cant differences in cognition or performance of activities of daily living function were found between multivitamin and placebo (30) . In the latter study, Kwok et al. found the concentration of Hcy was reduced to nearly 9 μ mol/L in a group of mild to moderate Alzheimer's disease patients supplemented with methylcobalamin and folic acid for 24 months as compared with a placebo group, but no signifi cant difference in any of the neuropsychological scores could be recorded between supplement group and placebo (31) . Since it is now well established that periconceptional folate supplementation is effective to reduce the risk of neural tube defects, the question as to whether Hcylowering therapy would be also effective for reducing the risk of other pregnancy complications is probably pleonastic and anachronistic (32) . Regardless of speculative considerations, the conclusions of several observational studies on vitamin B supplementation and adverse pregnancy outcomes including miscarriage, gestational diabetes, premature rupture of the membranes, placental abruption, have been questioned for a variety of methodological drawbacks, which preclude drawing defi nitive conclusions (33) .
Therefore, we are now facing a tangible paradox, whereby epidemiological evidence strongly supports the association between Hcy and human disease, reliable biological mechanisms have been provided to justify the pathogenetic role of this sulfur-containing compound (e.g., direct injury to vascular structure and function, or promoting atherosclerosis by enhancing the atherogenicity of cholesterol-rich lipoproteins, especially lipoprotein[a]) (34) , but yet most intervention trials have failed to show any signifi cant clinical benefi t from homocysteine-lowering therapy. It is thereby reasonable to reiterate the question as to whether Hcy has definitely shrunk (35) (36) . Fenofi brate is a lipid regulating agent of the fi brate class, which is administered to lower triglycerides and cholesterol to a lesser extent. The preliminary results of the FIELD study have already highlighted a slightly higher incidence of pancreatitis, deep venous thrombosis, and pulmonary embolism associated with this drug (37) , which has paved the way to further scrutiny. In this subsequent analysis of FIELD trial, the concentration of Hcy signifi cantly increased by 6.5 μ mol/L during fenofi brate therapy, a change that was fully reversible in the placebo group but persisted in the treatment group until reversing at the end of therapy (36) . Throughout follow-up, the rate of venous thromboembolism was nearly double in fenofi brate than in placebo group (2.17 % vs. 1.43 % ; p = 0.006). After adjustment for potential confounders, baseline Hcy and the fenofi brate therapy persisted as signifi cant independent predictors of thrombosis risk, and each 5 μ mol/L higher baseline Hcy was associated with 19 % higher risk of VTE in multivariate analysis. The interaction between fenofi brate and hyperhomocysteinemia was greater in patients with the highest baseline Hcy levels, thus providing reliable clue on the existence of a biological interaction between Hcy and fenofi brate.
Conclusions
According to the current state of scientifi c knowledge, it seems thus reasonable to conclude that lowering Hcy alone is probably insuffi cient to mitigate the risk of thromboembolic, cardiovascular and neurodegenerative disorders inasmuch as this bizarre amino acid acts in strict synergy with other probably more powerful risk factors. Several lines of evidence suggest, however, that its measurement may be helpful for identifying subjects at greater risk of disease, who may thus benefi t from a more aggressive treatment of other modifi able risk factors. This is indeed in agreement with the outcome of the FIELD trial, in which Hcy was found to be a signifi cant predictor of thrombotic events in the entire cohort (with a relative risk comparable to that previously reported by den Heijer et al., i.e., 19 % vs. 27 % ), but not in the placebo group (36) . It is also noteworthy that a positive association has been observed between dyslipidemia, especially hypercholesterolemia, and venous thromboembolism. Therapy with hypolipidemic agents has henceforth been provocatively suggested for preventing venous thrombosis on the background that statins and other cholesterol-lowering drugs may exert a pleiotropic, protective effect against hypercholesterolemia, endothelium dysfunction, platelet hyperreactivity and excessive thrombin generation (38, 39) . According to the valuable data gathered from the FIELD trial, the potential benefi ts of fenofi brate in lowering triglycerides and cholesterol should however be carefully weighted against its potential metabolic interaction with Hcy.
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